Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Díaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M; Aide et Recherche en Cancerologie Digestive Group.

JAMA Netw Open. 2019 Sep 4;2(9):e1911750. doi: 10.1001/jamanetworkopen.2019.11750.

2.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

3.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

4.

The Budding Yeast Ubiquitin Protease Ubp7 Is a Novel Component Involved in S Phase Progression.

Böhm S, Szakal B, Herken BW, Sullivan MR, Mihalevic MJ, Kabbinavar FF, Branzei D, Clark NL, Bernstein KA.

J Biol Chem. 2016 Feb 26;291(9):4442-52. doi: 10.1074/jbc.M115.671057. Epub 2016 Jan 6.

5.

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C.

J Clin Oncol. 2015 Dec 1;33(34):4093-8. doi: 10.1200/JCO.2015.61.6490. Epub 2015 Nov 2.

6.

Promotion of presynaptic filament assembly by the ensemble of S. cerevisiae Rad51 paralogues with Rad52.

Gaines WA, Godin SK, Kabbinavar FF, Rao T, VanDemark AP, Sung P, Bernstein KA.

Nat Commun. 2015 Jul 28;6:7834. doi: 10.1038/ncomms8834.

7.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

8.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ.

J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10.

9.

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF.

Anticancer Res. 2013 Aug;33(8):2997-3004.

PMID:
23898052
10.

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF.

Eur J Cancer. 2013 Sep;49(13):2841-50. doi: 10.1016/j.ejca.2013.04.019. Epub 2013 May 28.

11.

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.

Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS.

Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

PMID:
23708063
12.

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J.

J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.

13.

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.

Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2013 Apr 15;119(8):1547-54. doi: 10.1002/cncr.27947. Epub 2013 Jan 18.

14.

Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Dec 1;118(23):5777-82. doi: 10.1002/cncr.27607. Epub 2012 May 17.

15.

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A.

Eur J Cancer. 2012 May;48(8):1126-32. doi: 10.1016/j.ejca.2012.02.052. Epub 2012 Mar 15.

PMID:
22424880
16.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Eur Urol. 2012 May;61(5):888-95. doi: 10.1016/j.eururo.2012.01.012. Epub 2012 Jan 18.

PMID:
22269604
17.

Systemic therapy for metastatic renal cell carcinoma: a review and update.

Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF.

Rev Urol. 2012;14(3-4):65-78.

18.

Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.

Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2012 Feb;187(2):418-23. doi: 10.1016/j.juro.2011.10.024. Epub 2011 Dec 15.

PMID:
22177164
19.

The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Dec;186(6):2168-74. doi: 10.1016/j.juro.2011.07.068. Epub 2011 Oct 19.

PMID:
22014797
20.

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Apr 1;118(7):1795-802. doi: 10.1002/cncr.26453. Epub 2011 Aug 25.

21.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Jan;185(1):30-5. doi: 10.1016/j.juro.2010.09.013. Epub 2010 Nov 12.

PMID:
21074210
22.

Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jul;184(1):53-8. doi: 10.1016/j.juro.2010.03.026. Epub 2010 May 15.

PMID:
20478577
23.

Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.

Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jun;183(6):2143-7. doi: 10.1016/j.juro.2010.02.023.

PMID:
20399450
24.

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.

Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2010 Feb 1;116(3):616-24. doi: 10.1002/cncr.24768.

25.

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP.

J Cancer Res Clin Oncol. 2010 May;136(5):737-43. doi: 10.1007/s00432-009-0712-3. Epub 2009 Nov 11.

26.

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.

Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A; Investigators of the BRiTE study.

Oncologist. 2009 Sep;14(9):862-70. doi: 10.1634/theoncologist.2009-0071. Epub 2009 Sep 2.

27.

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.

de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

J Urol. 2009 Aug;182(2):728-34. doi: 10.1016/j.juro.2009.03.077. Epub 2009 Jun 18.

PMID:
19539328
28.

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900. doi: 10.1158/1055-9965.EPI-08-0786. Epub 2009 Feb 24.

29.

Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.

Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao JY, Thomas GV, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2009 Apr;181(4):1558-64; discussion 1563-4. doi: 10.1016/j.juro.2008.11.098. Epub 2009 Feb 23.

PMID:
19230920
30.

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.

Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS.

Clin Cancer Res. 2009 Feb 15;15(4):1162-9. doi: 10.1158/1078-0432.CCR-08-1229.

31.

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Clin Oncol. 2009 Feb 10;27(5):746-53. doi: 10.1200/JCO.2007.15.8345. Epub 2009 Jan 5.

PMID:
19124809
32.

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O.

J Clin Oncol. 2009 Jan 10;27(2):199-205. doi: 10.1200/JCO.2008.17.7931. Epub 2008 Dec 8.

PMID:
19064978
33.

Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ.

Cancer. 2008 Nov 1;113(9):2457-63. doi: 10.1002/cncr.23851.

34.

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.

Kabbinavar FF, Wallace JF, Holmgren E, Yi J, Cella D, Yost KJ, Hurwitz HI.

Oncologist. 2008 Sep;13(9):1021-9. doi: 10.1634/theoncologist.2008-0003. Epub 2008 Sep 5.

35.

Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.

Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Cancer. 2008 Oct 1;113(7):1641-8. doi: 10.1002/cncr.23769.

36.

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.

Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS.

BJU Int. 2008 Sep;102(6):692-6. doi: 10.1111/j.1464-410X.2008.07660.x. Epub 2008 Apr 10.

37.

Pathobiology and prognosis of chromophobe renal cell carcinoma.

Klatte T, Han KR, Said JW, Böhm M, Allhoff EP, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2008 Nov-Dec;26(6):604-9. doi: 10.1016/j.urolonc.2007.07.015. Epub 2008 Jan 14.

PMID:
18367104
38.

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.

Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2008 May;179(5):1719-26. doi: 10.1016/j.juro.2008.01.018. Epub 2008 Mar 17.

PMID:
18343437
39.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

40.

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.

Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ.

J Urol. 2008 Jan;179(1):61-6. Epub 2007 Nov 13.

PMID:
17997430
41.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D.

J Clin Oncol. 2007 Oct 10;25(29):4536-41. Epub 2007 Sep 17.

PMID:
17876014
42.

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.

Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF.

BJU Int. 2007 Oct;100(4):765-9.

43.

Prognostic factors for renal cell carcinoma with tumor thrombus extension.

Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS.

J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195. Epub 2007 Aug 14.

PMID:
17698087
44.

Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.

Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS.

J Urol. 2007 Jul;178(1):35-40; discussion 40. Epub 2007 May 22.

PMID:
17521678
45.

Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.

Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ.

J Urol. 2007 Jun;177(6):2081-6; discussion 2086-7.

PMID:
17509291
46.

Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.

Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ.

BJU Int. 2007 Jul;100(1):21-5. Epub 2007 Apr 13.

47.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS.

J Clin Oncol. 2006 Jul 20;24(21):3451-7.

PMID:
16849761
48.

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S.

J Clin Oncol. 2005 Jun 1;23(16):3706-12. Epub 2005 May 2.

PMID:
15867200
49.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.

J Clin Oncol. 2005 Jun 1;23(16):3697-705. Epub 2005 Feb 28.

PMID:
15738537
50.

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Kabbinavar FF, Ellis LM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. Review.

PMID:
15479482

Supplemental Content

Loading ...
Support Center